Viking Therapeutics, Inc. ( VKTX) - Key Metrics
VKTX Revenue per Share metrics
| Date | Revenue per Share | Net Income per Share | Operating Cash Flow | Free Cash Flow per Share |
|---|---|---|---|---|
| 2026Q2 | $0 | -$1.10 | -$1.08 | -$1.08 |
| 2026Q1 | $0 | -$1.37 | -$0.99 | -$0.99 |
| 2025Q4 | $0 | -$1.38 | -$0.75 | -$0.75 |
| 2025Q3 | $0 | -$0.81 | -$0.84 | -$0.84 |
| 2025Q2 | $0 | -$0.58 | -$0.42 | -$0.42 |
VKTX Payout ratio and Price per Earnings ratio
| Date | Payout ratio | PE ratio |
|---|---|---|
| 2026Q2 | 0% | -8.87 |
| 2026Q1 | 0% | -5.94 |
| 2025Q4 | 0% | -6.37 |
| 2025Q3 | 0% | -8.11 |
| 2025Q2 | 0% | -11.42 |
VKTX
Price: $33.27
52 week price:
Earnings Per Share: -4.67 USD
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 1.7 million
Ebitda: -4.7 millionMarket Capitalization: 3.9 billion